Table 3.
Myocarditis and pericarditis events reported to EudraVigilance for the European Economic Area Datalock point 14 March 2022
Age group | Myocarditis | Pericarditis | ||||||||||||||
Male | Female | Sex not specified | Total | Male | Female | Sex not specified | Total | |||||||||
n | % | n | % | n | % | N | % | n | % | n | % | n | % | N | % | |
Comirnaty (Pfizer/BioNTech) | ||||||||||||||||
2 months–2 years | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 67 | 63.81 | 38 | 36.19 | 0 | 0.00 | 105 | 100.00 |
3–11 years | 4 | 66.67 | 2 | 33.33 | 0 | 0.00 | 6 | 100.00 | 798 | 48.33 | 848 | 51.36 | 5 | 0.30 | 1651 | 100.00 |
12–17 years | 507 | 86.82 | 72 | 12.33 | 5 | 0.86 | 584 | 100.00 | 164 | 56.75 | 125 | 43.25 | 0 | 0.00 | 289 | 100.00 |
18–64 years | 2302 | 70.16 | 956 | 29.14 | 23 | 0.70 | 3281 | 100.00 | 307 | 46.30 | 351 | 52.94 | 5 | 0.75 | 663 | 100.00 |
65–85 years | 130 | 50.58 | 125 | 48.64 | 2 | 0.78 | 257 | 100.00 | 54 | 46.55 | 62 | 53.45 | 0 | 0.00 | 116 | 100.00 |
85+ years | 12 | 52.17 | 11 | 47.83 | 0 | 0.00 | 23 | 100.00 | 1042 | 50.27 | 1026 | 49.49 | 5 | 0.24 | 2073 | 100.00 |
Not specified | 86 | 60.56 | 39 | 27.46 | 17 | 11.97 | 142 | 100.00 | 8 | 38.10 | 11 | 52.38 | 2 | 9.52 | 21 | 100.00 |
Total | 3041 | 70.84 | 1205 | 28.07 | 47 | 1.09 | 4293 | 100.00 | 2440 | 49.61 | 2461 | 50.04 | 17 | 0.35 | 4918 | 100.00 |
Spikevax (Moderna) | ||||||||||||||||
2 months–2 years | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 8 | 0.00 | 4 | 0.00 | 0 | 0.00 | 12 | 100.00 |
3–11 years | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 343 | 0.00 | 287 | 0.00 | 5 | 0.79 | 635 | 100.00 |
12–17 years | 69 | 92.00 | 6 | 8.00 | 0 | 0.00 | 75 | 100.00 | 39 | 0.00 | 45 | 0.00 | 0 | 0.00 | 84 | 100.00 |
18–64 years | 913 | 79.39 | 231 | 20.09 | 6 | 0.52 | 1150 | 100.00 | 0 | 0.00 | 2 | 100.00 | 0 | 0.00 | 2 | 100.00 |
65–85 years | 27 | 48.21 | 29 | 51.79 | 0 | 0.00 | 56 | 100.00 | 4 | 50.00 | 4 | 50.00 | 0 | 0.00 | 8 | 100.00 |
85+ years | 1 | 33.33 | 2 | 66.67 | 0 | 0.00 | 3 | 100.00 | 394 | 53.17 | 342 | 46.15 | 5 | 0.67 | 741 | 100.00 |
Not specified | 11 | 55.00 | 7 | 35.00 | 2 | 10.00 | 20 | 100.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | – |
Total | 1021 | 78.30 | 275 | 21.09 | 8 | 0.61 | 1304 | 100.00 | 788 | 53.17 | 684 | 46.15 | 10 | 0.67 | 1482 | 100.00 |
Overall (both mRNA vaccines) | ||||||||||||||||
2 months–2 years | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | – | 75 | 64.10 | 42 | 35.90 | 0 | 0.00 | 117 | 100.00 |
3–11 years | 4 | 66.67 | 2 | 33.33 | 0 | 0.00 | 6 | 100.00 | 1141 | 49.91 | 1135 | 49.65 | 10 | 0.44 | 2286 | 100.00 |
12–17 years | 576 | 87.41 | 78 | 11.84 | 5 | 0.76 | 659 | 100.00 | 203 | 54.42 | 170 | 45.58 | 0 | 0.00 | 373 | 100.00 |
18–64 years | 3215 | 72.56 | 1187 | 26.79 | 29 | 0.65 | 4431 | 100.00 | 307 | 46.17 | 353 | 53.08 | 5 | 0.75 | 665 | 100.00 |
65–85 years | 157 | 50.16 | 154 | 49.20 | 2 | 0.64 | 313 | 100.00 | 58 | 46.77 | 66 | 53.23 | 0 | 0.00 | 124 | 100.00 |
85+ years | 13 | 50.00 | 13 | 50.00 | 0 | 0.00 | 26 | 100.00 | 1436 | 51.03 | 1368 | 48.61 | 10 | 0.36 | 2814 | 100.00 |
Not specified | 97 | 59.88 | 46 | 28.40 | 19 | 11.73 | 162 | 100.00 | 8 | 38.10 | 11 | 52.38 | 2 | 9.52 | 21 | 100.00 |
Total | 4058 | 72.55 | 1480 | 26.46 | 55 | 0.98 | 5593 | 100.00 | 3228 | 50.44 | 3145 | 49.14 | 27 | 0.42 | 6400 | 100.00 |
Percentages per age group are presented.
mRNA, messenger RNA.